Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort

Brosseau, Solenn; Danel, Claire; Scherpereel, Arnaud; Mazières, Julien; Lantuéjoul, Sylvie; Margery, J.; Greillier, L.; Audigier-Valette, Clarisse; Gounant, V.; Antoine, Martine; Moro-Sibilot, Denis; Rouquette, Isabelle; Molinier, Olivier; Corre, Romain; Monnet, Isabelle; Langlais, Alexandra; Morin, Franck; Bergot, Emmanuel; Zalcman, Gérard; Levallet, Guénaëlle

doi:10.1016/j.cllc.2019.04.010

Cited by 51 publications

(57 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Then, 299 duplicate publications were excluded, and 153 studies were screened by title and abstract. Subsequently, 119 studies were discarded and 34 studies 9 , 18 – 23 , 27 – 53 were left for eligibility assessment by full-text examination. Eighteen studies were excluded for different reasons: one study did not detect PD-L1 expression in sera samples other than tumor tissues, 37 11 studies did not present sufficient data for meta-analysis, 9 , 38 , 39 , 42 – 48 , 52 two studies did not use unique cut-off value, 40 , 50 one study did not test PD-L1 expression, 41 one study was a letter to the editor, 49 and two studies recruited patients with pleural and peritoneal mesothelioma tumors other than MPM.…”

Section: Resultsmentioning

confidence: 99%

“… 51 , 53 Finally, 16 studies were included in our meta-analysis. 18 – 23 , 27 – 36 The flow chart of the article screening process is shown in Figure 1 .…”

Section: Resultsmentioning

confidence: 99%

“… 18 , 20 – 22 , 27 – 36 All 16 studies 18 – 23 , 27 – 36 provided data on the association between PD-L1 and OS, whereas only two studies reported data on PFS. 19 , 30 With respect to treatment, seven studies enrolled patients receiving surgery, 18 , 27 – 29 , 31 , 35 , 36 three studies recruited patients receiving chemotherapy 19 , 33 or immunotherapy, 30 and six studies included patients receiving mixed treatments (chemotherapy, radiotherapy, and surgery). 20 – 23 , 32 , 34 The detailed information of antibody used in IHC for included studies is shown in Table 2 .…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

PD-L1 and prognosis in patients with malignant pleural mesothelioma: a meta-analysis and bioinformatics study

Jin¹,

Xie³

et al. 2020

Ther Adv Med Oncol

View full text Add to dashboard Cite

Background: The prognostic value of programmed death-ligand 1 (PD-L1) expression in patients with malignant pleural mesothelioma (MPM) has been controversial according to previous investigations. Therefore, we conducted a meta-analysis to assess the potential prognostic significance of PD-L1 expression in MPM. Methods: PubMed, Embase, Web of Science, Scopus, and the Cochrane Library were thoroughly searched for relevant original articles published before 9 April 2020. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) of overall survival (OS) and progression-free survival (PFS) were calculated. The results of the meta-analysis were verified using The Cancer Genome Atlas (TCGA) dataset. Results: In total 16 studies were included in our meta-analysis. A high PD-L1 expression was associated with a poor OS (HR = 1.53, 95% CI = 1.28–1.83, p < 0.001), but not a grave PFS (HR = 1.07, 95% CI = 0.82–1.39, p = 0.643) in MPM. Furthermore, the PD-L1 expression correlated with the sarcomatoid + biphasic type of MPM (odds ratio = 4.32, 95% CI = 2.16–8.64, p < 0.001). TCGA data indicated that PD-L1 was a significant prognostic factor for OS (HR = 2.069, 95% CI = 1.136–3.769, p = 0.0175), but not for PFS (HR = 1.205, 95% CI = 0.572–2.539, p = 0.624), which was in accordance with the results of the meta-analysis. Conclusion: A high PD-L1 expression is a significant prognostic factor for poor OS of patients with MPM. We therefore suggest that PD-L1 expression levels can be used to predict the clinical outcomes of patients with MPM in the future.

show abstract

Section: Resultsmentioning

confidence: 99%

“… 51 , 53 Finally, 16 studies were included in our meta-analysis. 18 – 23 , 27 – 36 The flow chart of the article screening process is shown in Figure 1 .…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

PD-L1 and prognosis in patients with malignant pleural mesothelioma: a meta-analysis and bioinformatics study

Jin¹,

Xie³

et al. 2020

Ther Adv Med Oncol

View full text Add to dashboard Cite

show abstract

“…PD-L1 is expressed by a substantial proportion of biphasic and sarcomatoid MPM cases, and its positivity above 1% is associated with a significant 10-months reduction in median OS compared to PD-L1 negative tumors [28,29]. Similarly, high PD-L1 expression (>50%) in epithelioid MPM patients correlates with shorter PFS (6.7 vs. 9.9 months) [28]. Despite its prognostic value [30][31][32], PD-L1 expression is not a valid predictive marker of response to anti-PD-L1 therapies for several tumor types [33,34], including MPM [35].…”

Section: Immunotherapy In Mpmmentioning

confidence: 99%

“…Recently, PD-L1 expression in malignant mesothelioma has been assessed on tissue microarrays using two different FDA-approved antibodies, and 22% to 27% of cases were positive for PD-L1 (1% cut off) [27]. PD-L1 is expressed by a substantial proportion of biphasic and sarcomatoid MPM cases, and its positivity above 1% is associated with a significant 10-months reduction in median OS compared to PD-L1 negative tumors [28,29]. Similarly, high PD-L1 expression (>50%) in epithelioid MPM patients correlates with shorter PFS (6.7 vs. 9.9 months) [28].…”

Section: Immunotherapy In Mpmmentioning

confidence: 99%

Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting

Nicolini

Bocchini

Angeli

et al. 2020

Cancers

View full text Add to dashboard Cite

Immunotherapy is the most promising therapeutic approach against malignant pleural mesothelioma (MPM). Despite technological progress, the number of targetable antigens or specific antibodies is limited, thus hindering the full potential of recent therapeutic interventions. All possibilities of finding new targeting molecules must be exploited. The specificity of targeting is guaranteed by the use of monoclonal antibodies, while fully human antibodies are preferred, as they are functional and generate no neutralizing antibodies. The aim of this review is to appraise the latest advances in screening methods dedicated to the identification and harnessing of fully human antibodies. The scope of identifying useful molecules proceeds along two avenues, i.e., through the antigen-first or binding-first approaches. The first relies on screening human antibody libraries or plasma from immunized transgenic mice or humans to isolate binders to specific antigens. The latter takes advantage of specific binding to tumor cells of antibodies present in phage display libraries or in responders’ plasma samples without prior knowledge of the antigens. Additionally, next-generation sequencing analysis of B-cell receptor repertoire pre- and post-therapy in memory B-cells from responders allows for the identification of clones expanded and matured upon treatment. Human antibodies identified can be subsequently reformatted to generate a plethora of therapeutics like antibody-drug conjugates, immunotoxins, and advanced cell-therapeutics such as chimeric antigen receptor-transduced T-cells.

show abstract

Higher concordance of PD‐L1 expression between biopsies and effusions in epithelioid than in nonepithelioid pleural mesothelioma

Mansour

Seidal

Mager

et al. 2021

Cancer Cytopathology

View full text Add to dashboard Cite

BACKGROUND: Malignant mesothelioma (MM) is a therapy-resistant tumor, often causing an effusion. Drugs targeting the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway have shown promising results, but assessment of PD-L1 expression to select patients for therapy has mainly been performed on histologic tissue samples. In a previous study, we showed that MM effusions are suitable for PD-L1 assessment with results comparable to those reported in histologic studies, but no studies have compared PD-L1 expression in histologic and cytologic samples. METHODS: PD-L1 expression was determined immunohistochemically (clone 28-8) in 61 paired samples of effusions and biopsies from patients with pleural MM, obtained at the time of diagnosis. Only cases with >100 tumor cells were included. Membranous staining in tumor cells was considered positive at ≥1%, >5%, >10%, and >50% cutoff levels. RESULTS: Of 61 histologic samples, PD-L1 expression was found in 28 and 7 samples at ≥1% and >50% cutoffs, respectively; the corresponding figures for cytology were 21 and 5, respectively. The overall percentage agreement between histology and cytology was 69% and 84%, with a kappa (κ) of 0.36 and 0.08 at ≥1% and >50% cutoffs, respectively. The concordance between cytology and histology tended to be higher for epithelioid MM versus nonepithelioid MM at a ≥1% cutoff. PD-L1 positivity in biopsies, but not in effusions, correlated with the histologic subtype at a ≥1% cutoff. CONCLUSIONS: A moderate concordance of PD-L1 expression between biopsies and effusions from pleural MM, especially for the epithelioid subtype, indicates biological differences between the 2 types of specimens. Cytology and histology may be complementary. Cancer Cytopathol 2021;0:1-11.

show abstract

Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort

Cited by 51 publications

References 19 publications

PD-L1 and prognosis in patients with malignant pleural mesothelioma: a meta-analysis and bioinformatics study

PD-L1 and prognosis in patients with malignant pleural mesothelioma: a meta-analysis and bioinformatics study

Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting

Higher concordance of PD‐L1 expression between biopsies and effusions in epithelioid than in nonepithelioid pleural mesothelioma

Contact Info

Product

Resources

About